GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Gross Profit

Avecho Biotechnology (ASX:AVE) Gross Profit : A$-0.04 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Gross Profit?

Avecho Biotechnology's gross profit for the six months ended in Dec. 2023 was A$-0.36 Mil. Avecho Biotechnology's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.04 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Avecho Biotechnology's gross profit for the six months ended in Dec. 2023 was A$-0.36 Mil. Avecho Biotechnology's Revenue for the six months ended in Dec. 2023 was A$0.03 Mil. Therefore, Avecho Biotechnology's Gross Margin % for the quarter that ended in Dec. 2023 was -1,340.74%.

Avecho Biotechnology had a gross margin of -1,340.74% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 13 years, the highest Gross Margin % of Avecho Biotechnology was 94.95%. The lowest was -9.30%. And the median was 70.84%.


Avecho Biotechnology Gross Profit Historical Data

The historical data trend for Avecho Biotechnology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Gross Profit Chart

Avecho Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.02 0.24 0.51 0.87 -0.04

Avecho Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.56 0.31 0.32 -0.36

Competitive Comparison of Avecho Biotechnology's Gross Profit

For the Biotechnology subindustry, Avecho Biotechnology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Gross Profit distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Gross Profit falls into.



Avecho Biotechnology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Avecho Biotechnology's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.474 - 0.518
=-0.04

Avecho Biotechnology's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.027 - 0.389
=-0.36

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.04 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Avecho Biotechnology's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=-0.36 / 0.027
=-1,340.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Avecho Biotechnology  (ASX:AVE) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Avecho Biotechnology had a gross margin of -1,340.74% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Avecho Biotechnology Gross Profit Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology (ASX:AVE) Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines